ReviewPathology oncology research : POR2013
Calreticulin and cancer.
Review in Pathology oncology research : POR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.Nanoscale advances · 2026Article
- Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease.Nature reviews. Nephrology · 2025Review
- Effects of artemisinin and cisplatin on the malignant progression of oral leukoplakia. In vitro and in vivo study.Journal of cancer research and clinical oncology · 2024Article
- Anticancer Effects of the Novel Pyrazolyl-Urea GeGe-3.International journal of molecular sciences · 2024Article
- DNA polymerase beta connects tumorigenicity with the circadian clock in liver cancer through the epigenetic demethylation of Per1.Cell death & disease · 2024Article
- Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.Frontiers in oncology · 2023Article
- Article
- Calreticulin enhances gastric cancer metastasis by dimethylating H3K9 in the E-cadherin promoter region mediating by G9a.Oncogenesis · 2022Article
- Research progress in inducing immunogenic cell death of tumor cells.Frontiers in immunology · 2022Review
- Lactoferrin: A Nutraceutical with Activity against Colorectal Cancer.Frontiers in pharmacology · 2022Review
- Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.Oncoimmunology · 2022Article
- Feiyanning Formula Induces Apoptosis of Lung Adenocarcinoma Cells by Activating the Mitochondrial Pathway.Frontiers in oncology · 2021Article
- Bone Marrow-Derived Mesenchymal Stem Cells Differentially Affect Glioblastoma Cell Proliferation, Migration, and Invasion: A 2D-DIGE Proteomic Analysis.BioMed research international · 2021Article
- Insights into the role of ERp57 in cancer.Journal of Cancer · 2021Review
- Structural Analysis of Calreticulin, an Endoplasmic Reticulum-Resident Molecular Chaperone.Progress in molecular and subcellular biology · 2021Article
- Calreticulin promotes EMT in pancreatic cancer via mediating CaJournal of experimental & clinical cancer research : CR · 2020Article
- Identification of Differentially Expressed Proteins from Smokeless Tobacco Addicted Patients Suffering from Oral Squamous Cell Carcinoma.Pathology oncology research : POR · 2020Article
- A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies.Clinical & translational immunology · 2020Article
- Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression.Cancers · 2020Article
- Calreticulin is a Critical Cell Survival Factor in Malignant Neoplasms.PLoS biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calreticulin (CRT) as a multi-functional endoplasmic reticulum protein is involved in a spectrum of cellular processes which ranges from calcium homeostasis and chaperoning to cell adhesion and finally malignant formation and progression. Previous studies have shown a contributing role for CRT in a range of different cancers. This present review will focus on the possible roles of CRT in the progression of malignant proliferation and the mechanisms involved in its contribution to cancer invasion.
Indexed as
Identifiers
23392843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.